- Introduction to Clinical Research Training
- Medical Education
- Dean for Medical Education
- Financial Aid
- MD Programs
- Curriculum Services
- Program Evaluation and Student Assessment
- Student Services
- The Academy at Harvard Medical School
- Anatomical Gift Program
- Teaching Awards
- Contact Us
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Office of Global Education
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
A New Look at Stomach Cancer
July 25, 2014
In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers at Harvard Medical School and Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.
In a report in Nature, investigators of The Cancer Genome Atlas Research Network said they analyzed 295 samples of gastric cancer, looking for ways to sort them into groups with similar key DNA defects and molecular aberrations. It was extremely important, they said, to identify categories that would be useful in guiding therapy for patients.
“We clearly converged on four groups of gastric cancer with distinct features and classes of molecular alterations,” said the report’s corresponding author, Adam Bass, HMS assistant professor of medicine at Dana-Farber and Brigham and Women’s Hospital and corresponding author of the report. He is director for translational research at the Center for Esophageal and Gastric Cancer at Dana-Farber and an associate member of the cancer program at the Broad Institute of MIT and Harvard.
Grouping the cancers in this way will help researchers enroll patients in clinical trials that test drugs designed to target their particular stomach cancer subtype, said Bass. There is an urgent need for new therapies, he said, because “these are aggressive cancers and the five-year survival rate is between 20 and 25 percent.”
Gastric adenocarcinomas—the vast majority of stomach cancers—cause more than 700,000 deaths worldwide each year. The American Cancer Society estimates that 22,220 cases will be diagnosed in the United States in 2014, with about 10,990 deaths. Stomach cancer is mainly a disease of elderly people. Infection with the bacterium Helicobacter pylori (H. pylori) is a major cause. Other risk factors include diet, smoking, geography and ethnicity, and some inherited cancer syndromes.
Research on the biology of stomach cancer and the development of new therapies has been difficult because of its diversity and the presence of different pathological forms.
The new study is part of The Cancer Genome Atlas (TCGA) project, a federally funded initiative that involves large international groups of researchers and centers cataloging genomic characteristics across a spectrum of different forms of cancer.
The gastric cancer research team collected frozen tissue specimens and blood samples from 295 patients who had not been treated with chemotherapy or radiation. The tissue specimens, from hospitals around the world, were analyzed with six different molecular analysis technologies. When computational methods were applied to the large amount of resulting data, the cancers fell into the following four subtypes
Tumors containing the Epstein-Barr virus, along with mutations in the PIK3CA gene pathway, extreme DNA hypermethylation and extra copies of PD-L1 and PD-L2 genes made up about 10 percent of the cancers. Bass said these results suggest that inhibitors of the PI3-K pathway could have great utility in these cancers. Furthermore, he said, the findings of elevated levels of PD-L1 and PD-L2, key regulators of the immune response, suggest that emerging immunotherapy agents be tested in these patients.
Tumors in which malfunctioning DNA repair mechanisms cause a high rate of mutations novel precision drugs accounted for about 20 percent of tumors. Many of these lead to potential activation of cancer-related signaling proteins that can be targeted with novel precision drugs.
The largest category of tumors, making up about half of the cancer specimens, was termed “chromosomally unstable.” These cancer cells contained a jumble of extra or missing pieces of genes and chromosomes. Bass said these tumors “have a striking number of genomic amplifications of key cancer-promoting genes” for which targeted therapies exist or are in development. This subtype of tumor is frequently found in the junction between the stomach and the esophagus, and is a type of stomach cancer that has been dramatically increasing in the United States, he said.
The fourth group was termed “genomically stable,” as they lacked the molecular features of the other three types. These tumors, making up 20 percent of the specimens were largely those of a specific class of gastric cancer called diffuse-type tumors. “These tumors are especially deadly because of their ability to metastasize rapidly and because we lack effective therapies,” said Bass. The team identified a novel set of genomic alterations in a pathway called the RHOA signaling pathway in about 30 percent of these tumors. “This finding result opens up an entirely new line of research to allow us to investigate what underlies this deadly form of gastric cancer and to ultimately develop new therapies,” said Bass.
The research was supported by NIH grants 5U24CA143799, 5U24CA143835, 5U24CA143840, 5U24CA143843, 5U24CA143845, 5U24CA143848, 5U24CA143858, 5U24CA143866, 5U24CA143867, 5U24CA143882, 5U24CA143883, 5U24CA144025, U54HG003067, U54HG003079, U54HG003273 and P30CA16672.
Adapted from a Dana-Farber news release.